Literature DB >> 1648562

Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.

V Liepkalns1, H Durand, C Bougeret.   

Abstract

Addition of purified plasmin or plasminogen (0.1 microM) to serum-free culture media elevated cellular D-myo-inositol 1,4,5-trisphosphate (InsP3) levels in human colorectal carcinoma cells within 1 h to double those of control cells. This was accompanied by decreases in cellular phosphatidylinositol bisphosphate by 40% in cells exposed to fibrinolytic ligands for up to 1 h. The effect was not due to opening of Ca2+ channels of the type blocked by 5 microM nifedipine, and 100 microM EGTA, a Ca2+ chelator, did not suppress plasmin's ability to elevate InsP3. Binding assays at 4 degrees C with 125I-labelled plasmin indicated maximum binding within 1 h suggesting that the effects of plasmin may be associated with its cell-binding function. These cells could convert exogenous plasminogen to plasmin with endogenous activation and this was accompanied by a decrease in radioactive phosphatidylinositol well below control levels (13% of control). Our results contribute to evidence for the association of plasmin-binding sites with a signalling system. A cell signalling system indirectly or directly associated with plasmin binding, would permit carcinoma cells to coordinate extracellular fibrinolysis with cell migration and motility through second messengers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648562     DOI: 10.1007/bf01630715

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover.

Authors:  A Ashkenazi; J W Winslow; E G Peralta; G L Peterson; M I Schimerlik; D J Capon; J Ramachandran
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

2.  Characterization of multiple forms of phosphoinositide-specific phospholipase C purified from human platelets.

Authors:  M G Low; R C Carroll; A C Cox
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

Review 3.  Inositol phosphates: synthesis and degradation.

Authors:  P W Majerus; T M Connolly; V S Bansal; R C Inhorn; T S Ross; D L Lips
Journal:  J Biol Chem       Date:  1988-03-05       Impact factor: 5.157

4.  Vasoactive intestinal polypeptide and glucagon: stimulation of adenylate cyclase activity via distinct receptors in liver and fat cell membranes.

Authors:  B Desbuguois; M H Laudat; P Laudat
Journal:  Biochem Biophys Res Commun       Date:  1973-08-21       Impact factor: 3.575

5.  Receptor for plasmin on human carcinoma cells.

Authors:  P Burtin; M C Fondaneche
Journal:  J Natl Cancer Inst       Date:  1988-07-20       Impact factor: 13.506

6.  Phosphatidylinositol 4,5-bisphosphate turnover is transient while phosphatidylinositol turnover is persistent in thyrotropin-releasing hormone-stimulated rat pituitary cells.

Authors:  A Imai; M C Gershengorn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells.

Authors:  E C Kohn; L A Liotta; E Schiffmann
Journal:  Biochem Biophys Res Commun       Date:  1990-01-30       Impact factor: 3.575

8.  Dihydropyridine calcium channel activators and antagonists influence depolarization-evoked inositol phospholipid hydrolysis in brain.

Authors:  D A Kendall; S R Nahorski
Journal:  Eur J Pharmacol       Date:  1985-09-10       Impact factor: 4.432

9.  Alterations in expression and synthesis of glycolipid antigens in human colonic tumor cell lines.

Authors:  V A Liepkalns; E Herrero-Zabaleta; M C Fondaneche; P Burtin
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

10.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.

Authors:  E F Plow; D E Freaney; J Plescia; L A Miles
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.